Hydrogenology
Hydrogenology editorial study record

Effectiveness of hydrogen rich water on antioxidant status of subjects with potential metabolic syndrome—an open label pilot study

Nakao A et al. · J Clin Biochem Nutr. 2010;46(2):140–149.

HumanH₂-rich waterPublished 2010
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Human

Reported design

Open-label single-site pilot study

Research topic

Metabolic and lipid health

Administration classification

H₂-rich water

Study result signal

Not reported in this record.

Outcome type

Not reported in this record.

Reported in the source

Methods at a glance

Population or model

Adults aged 40 or older with potential metabolic syndrome

Sample

20 participants

Duration

8 weeks

Intervention

Participants drank 300–400 mL from each of five prepared bottles daily: 1.5–2.0 L/day total

Hydrogen form

H₂ dissolved in water — H₂ only, not Brown’s gas.

H₂ specification

0.55–0.65 mM dissolved H₂, generated with magnesium sticks; reported pH 7.9–8.1.

H₂ flow

Not applicable — oral water, not gas inhalation.

O₂ delivered with H₂

No O₂ was co-delivered as part of the intervention.

Comparator

No placebo comparator

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Oxidative-stress, lipid, glucose and safety measures

Reported result

From baseline, the paper reports SOD increased 39% and urinary TBARS decreased 43% at week 8 (both p<0.05); HDL increased 8% and total cholesterol/HDL ratio decreased 13% at week 4; fasting glucose did not change.

Results-extraction completeness

Methods and principal results checked in the free full text; independent risk-of-bias appraisal remains incomplete.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

Open-label, single-site pilot with 20 participants and no placebo comparator; within-group changes and mainly laboratory outcomes are vulnerable to bias.

Applies directly to

Adults aged 40 or older described as having potential metabolic syndrome in this study.

Preliminary appraisal framework

Cochrane guidance for uncontrolled before-after studies · biomarker changes

Preliminary risk-of-bias status

High risk for causal interpretation — preliminary

Appraisal rationale

Open-label single-arm study with no concurrent comparator. Time trends, behavior changes, regression to the mean and selective reporting cannot be separated from an intervention effect.

Appraisal domains

High risk — no random allocation or comparator. · High risk — participants and investigators knew the intervention; co-interventions and behavioral changes are difficult to exclude. · Some concerns — full-text follow-up is reported, but attrition handling requires structured verification. · Some concerns — laboratory measures are objective, but collection and analysis were not blinded by a comparator design. · Some concerns — many biomarkers and time points; no prespecified public analysis plan was identified.

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 20216947 · DOI: 10.3164/jcbn.09-100

Publisher access

Open-access full text is available through PMC and J-STAGE.

Extraction basis

Free full text on PMC; bibliographic identifiers cross-checked in PubMed.

Record revision

2026-08-10